Background Heteroresistance is a phenotype in which a clinically susceptible bacterial isolate contains less susceptible subpopulations. Unexpectedly high levels of treatment failure for cefiderocol, a novel antibiotic designed to treat multidrug-resistant infections, have been attributed to this phenomenon. Objectives To determine prevalence of cefiderocol heteroresistance amongst clinical isolates at a North London tertiary care centre and study the population dynamics upon exposure to the antibiotic. Methods Gram-negative clinical isolates (n = 146) were screened for cefiderocol susceptibility by standard disc diffusion and Etest assays. Isolates were classified based on EUCAST breakpoints for cefiderocol susceptibility. Heteroresistance was confirmed by performing modified-population analysis profile (mPAP) assay in iron-depleted Mueller Hinton II agar. MIC values were determined by broth microdilution (BMD) assay as per EUCAST guidelines. The heteroresistant isolates and their corresponding less susceptible subpopulations were serially passaged in media with sub-inhibitory concentrations of cefiderocol as well as in cefiderocol-free medium. The changes in frequency and/or susceptibility in the heteroresistant subpopulation were detected using mPAP. Results Eleven heteroresistant (7.53%) and twenty-two resistant (15.06%) isolates were identified. Cefiderocol susceptibility of the heteroresistant isolates after five passages in cefiderocol-free medium partially reverted to that of the parent population. However, this phenomenon was not observed in the cohort that was first passaged in cefiderocol-containing medium before passages in cefiderocol-free medium. When heteroresistant populations were passaged in cefiderocol-containing media at 0.25× MIC values, no MIC changes were observed after five serial passages; however, the proportion of less susceptible subpopulations increased by 1.2 log10 in one out of five isolates. Nevertheless, when the antibiotic pressure was removed by passaging in cefiderocol-free media for a further five serial passages, the MIC and/or frequency of the less susceptible colonies within the heteroresistant population further increased in 80% of the passaged isolates. In one isolate, the MIC of the heteroresistant sub-population increased by >32-fold while the frequency of the heteroresistant sub-population increased by 1.0 log10 in another. Conclusions The prevalence of heteroresistance to cefiderocol was around 7% amongst clinical isolates. The heteroresistant phenotypes were unstable unless exposed to cefiderocol. Such exposure may also increase the MIC and/or frequency of less susceptible cells within the heteroresistant population. This amplification can continue even after removal of antibiotic pressure. Developing methods for detecting heteroresistance to cefiderocol in clinical laboratories is essential. Clinicians need to take this phenomenon into account when planning treatment regimens to optimize the effectiveness of this invaluable addition to the antimicrobial armamentarium.
A total number of 201 various clinical samples were processed during the study. 91 strains of Klebsiella pneumoniae were isolated. They were studied for ESBL production by screening test, CLSI disc diffusion method & phenotypic confirmation by disc potentiation test. RESULT:-Out of 91 strains, 71 were found positive for ESBL production by screening test. Out of 71 strains 59 were confirmed by disc potentiation test. So out of 91 strains 59 (64.8%) were confirmed as ESBL producers. Among the ESBL producer Klebsiella pneumoniae, 11(18.64%) were sensitive to Cefotaxime, 06(10.16%) to Ceftriaxone & 10(16.94%) to Ceftazidime by routine Kirby Bauer disc diffusion method. All the Klebsiella pneumoniae isolates were sensitive to Imipenem. Resistance against Ampicillin (10ug) is 100%, Ciprofloxacin (5ug) is 93.22%, Gentamicin (10ug) is 88.13%, Tetracycline (30ug) is 72.9% and Amikacin (30ug) is 18.64%. CONCLUSION: Our study shows presence of ESBL producer Klebsiella pneumoniae in clinical specimens and their prevalence is 64.8%. The routine antimicrobial sensitivity test may fail to detect ESBL. Detection of ESBL production should be carried out as a routine in diagnostic laboratories by disc potentiation test as it is a simple and cost effective test. Antibiotics resistance is significantly more prevalent in ESBL positive isolates as compared to ESBL negative.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.